Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

322.64 +1.77 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Expert Ratings for Alnylam Pharmaceuticals
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals
Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam... 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis
Via Benzinga
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET
Alnylam Pharmaceuticals (NASDAQ:ALNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
World Markets News For Friday
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
Alnylam Hits Pfizer, Moderna With Patent Infringement Suits
Via Benzinga
What 8 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter. 
Via Benzinga
Expert Ratings For Alnylam Pharmaceuticals
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Alnylam Pharmaceuticals: Q4 Earnings Insights
  Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q4 earnings results on Thursday, February 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-... 
Via Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts... 
Via Talk Markets
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss... 
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.